Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.53 |
| ▸ | HRH1 | P35367 | 6/20 | 0.50 |
| ▸ | HRH2 | P25021 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445904 | 0.90 | HRH3 (0.54) | HRH3HRH1HRH2 | |
| SCHEMBL14918688 | 0.76 | HDAC6 (0.49) | HRH3HRH1HRH2KDM4E | |
| SCHEMBL7546222 | 0.76 | HRH3 (0.55) | HRH3HRH1ALDH1A1 | |
| SCHEMBL4254124 | 0.76 | MAPT (0.58) | ALDH1A1 | |
| SCHEMBL4253993 | 0.73 | NPC1 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL4248722 | 0.71 | LMNA (0.36) | HRH3KDM4EALDH1A1 | |
| SCHEMBL9079217 | 0.71 | HRH3 (0.53) | HRH3HRH1ALDH1A1 | |
| SCHEMBL4249828 | 0.70 | HRH3 (0.49) | HRH3ALDH1A1 | |
| SCHEMBL7398284 | 0.70 | HRH3 (0.58) | HRH3HRH1ALDH1A1 | |
| SCHEMBL4251760 | 0.70 | HPGD (0.48) | HRH3KDM4EALDH1A1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023798-A1 | THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC8, HDAC3 | HRH3 198/4885HRH1 503/4885HRH2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.